Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2025 Filed Feb 18, 2025 22:53 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 636 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001880 · doc4.xml · nonDerivative · entry 3 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 1,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 11 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,273 Underlying: Common Stock · 1,273 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
Tax withholdingCommon Stock | 581 | $106.11 | $61,649.91 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 5 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,135 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionCommon Stock | 1,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 4 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 20 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 85 Underlying: Common Stock · 85 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 16 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 Underlying: Common Stock · 990 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 30 | $106.11 | $3,183.30 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 10 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,667 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 9 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 291 | $106.11 | $30,878.01 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 4 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,071 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 3 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionRestricted Stock Units · Derivative | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · derivative · entry 10 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,970 Underlying: Common Stock · 2,970 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 1,355 | $106.11 | $143,779.05 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · nonDerivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,826 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 11 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,265 Underlying: Common Stock · 16,265 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 7,865 | $106.11 | $834,555.15 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,643,885 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,651,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 11 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,960 Underlying: Common Stock · 3,960 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 1,806 | $106.11 | $191,634.66 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,272 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · derivative · entry 11 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,546 Underlying: Common Stock · 2,546 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,231 | $106.11 | $130,621.41 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · nonDerivative · entry 4 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,716 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · nonDerivative · entry 3 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 10 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,839 Underlying: Common Stock · 1,839 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 890 | $106.11 | $94,437.90 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,155 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 10 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,243 Underlying: Common Stock · 4,243 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,052 | $106.11 | $217,737.72 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,781 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:53 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001880 · doc4.xml · derivative · entry 9 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,322 Underlying: Common Stock · 661 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:53 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 315 | $106.11 | $33,424.65 |
DisclosureSEC source: 0001225208-25-001880 · doc4.xml · nonDerivative · entry 2 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,552 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:53 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001880 · doc4.xml · nonDerivative · entry 1 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 10 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,230 Underlying: Common Stock · 2,115 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
SaleCommon Stock | 1,201 | $106.31 | $127,678.31 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,443 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
Tax withholdingCommon Stock | 965 | $106.11 | $102,396.15 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,644 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionCommon Stock | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 106 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 19 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 212 Underlying: Common Stock · 106 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 15 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,248 Underlying: Common Stock · 1,123 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 38 | $106.11 | $4,032.18 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 8 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,612 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 106 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 7 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 330 | $106.11 | $35,016.30 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 2 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,372 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 1,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · nonDerivative · entry 1 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionRestricted Stock Units · Derivative | 2,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · derivative · entry 9 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,552 Underlying: Common Stock · 2,776 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 1,266 | $106.11 | $134,335.26 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,211 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 10 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,048 Underlying: Common Stock · 16,524 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 7,990 | $106.11 | $847,818.90 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,635,485 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,643,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,725 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 1,990 | $106.11 | $211,158.90 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,118 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.